SEARCH

SEARCH BY CITATION

References

  • Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ et al. (2007). Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10: 870879.
  • Beaulieu P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V et al. (2000). Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 396: 8592.
  • Bingham S, Beswick PJ, Bountra C, Brown T, Campbell IB, Chessell IP et al. (2005). The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther 312: 11611169.
  • Bisogno T, Melck D, Bobrov M, Gretskaya NM, Bezuglov VV, De Petrocellis L et al. (2000). N-Acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351 (Part 3): 817824.
  • Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V (1997). Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322 (Part 2): 671677.
  • Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277281.
  • Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ et al. (2006). Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148: 102113.
  • Chen P, Hu S, Yao J, Moore SA, Spector AA, Fang X (2005). Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc Res 69: 2835.
  • Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT (2002). CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96: 253260.
  • Costa B, Conti S, Giagnoni G, Colleoni M (2002). Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 137: 413420.
  • Costa B, Siniscalco D, Trovato AE, Comelli F, Sotgiu ML, Colleoni M et al. (2006). AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol 148: 10221032.
  • Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 93719376.
  • Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 8387.
  • Cravatt BF, Lichtman AH (2004a). The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61: 149160.
  • Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH (2004b). Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 101: 1082110826.
  • D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V (2006). Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20: 568570.
  • Day TA, Rakhshan F, Deutsch DG, Barker EL (2001). Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol Pharmacol 59: 13691375.
  • de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Viso A, Lopez-Rodriguez ML, Ramos JA (2002). UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur J Pharmacol 449: 99103.
  • de Lago E, Petrosino S, Valenti M, Morera E, Ortega-Gutierrez S, Fernandez-Ruiz J et al. (2005). Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem Pharmacol 70: 446452.
  • Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 19461949.
  • Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99: 1081910824.
  • Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V (2004). Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20: 23112320.
  • Elmes SJ, Winyard LA, Medhurst SJ, Clayton NM, Wilson AW, Kendall DA et al. (2005). Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 118: 327335.
  • Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92: 33763380.
  • Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G et al. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352358.
  • Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A et al. (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 101: 87568761.
  • Fields HL, Basbaum AI, Heinricher MM (2006). Central nervous system mechanisms of pain modulation. In: McMahon SB, Koltzenburg M (eds). Textbook of Pain. Elsevier Limited: Philadelphia, pp 125142.
  • Fowler CJ, Holt S, Tiger G (2003). Acidic nonsteroidal anti-inflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner. J Enzyme Inhib Med Chem 18: 5558.
  • Fowler CJ, Jonsson KO, Tiger G (2001). Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochem Pharmacol 62: 517526.
  • Francischi JN, Chaves CT, Moura AC, Lima AS, Rocha OA, Ferreira-Alves DL et al. (2002). Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol 137: 837844.
  • Ghilardi JR, Svensson CI, Rogers SD, Yaksh TL, Mantyh PW (2004). Constitutive spinal cyclooxygenase-2 participates in the initiation of tissue injury-induced hyperalgesia. J Neurosci 24: 27272732.
  • Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG (2003). Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100: 42694274.
  • Glaser ST, Kaczocha M, Deutsch DG (2005). Anandamide transport: a critical review. Life Sci 77: 15841604.
  • Goparaju SK, Ueda N, Taniguchi K, Yamamoto S (1999). Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57: 417423.
  • Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S (1998). Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 422: 6973.
  • Guindon J, Desroches J, Beaulieu P (2007). The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150: 693701.
  • Guindon J, LoVerme J, De Lean A, Piomelli D, Beaulieu P (2006). Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides Eur J Pharmacol 550: 6877.
  • Hermann A, Kaczocha M, Deutsch DG (2006). 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. AAPS J 8: E409412.
  • Hillard CJ, Jarrahian A (2005). Accumulation of anandamide: evidence for cellular diversity. Neuropharmacology 48: 10721078.
  • Hogestatt ED, Jonsson BA, Ermund A, Andersson DA, Bjork H, Alexander JP et al. (2005). Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280: 3140531412.
  • Hohmann AG, Suplita II RL (2006). Endocannabinoid mechanisms of pain modulation. AAPS J 8: E693708.
  • Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 11081112.
  • Holt S, Comelli F, Costa B, Fowler CJ (2005). Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146: 467476.
  • Holt S, Nilsson J, Omeir R, Tiger G, Fowler CJ (2001). Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. Br J Pharmacol 133: 513520.
  • Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F et al. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99: 84008405.
  • Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 1052910533.
  • Jansen AS, Farkas E, Mac Sams J, Loewy AD (1998). Local connections between the columns of the periaqueductal gray matter: a case for intrinsic neuromodulation. Brain Res 784: 329336.
  • Jarrahian A, Manna S, Edgemond WS, Campbell WB, Hillard CJ (2000). Structure–activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J Neurochem 74: 25972606.
  • Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147: 281288.
  • Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V (2006). Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26: 1331813327.
  • Kalant H (2004). Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28: 849863.
  • Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 7681.
  • Khanolkar AD, Abadji V, Lin S, Hill WA, Taha G, Abouzid K et al. (1996). Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 39: 45154519.
  • Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R et al. (2002a). Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277: 4487744885.
  • Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE, DuBois RN et al. (2002b). 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 277: 2327823286.
  • Kozak KR, Prusakiewicz JJ, Marnett LJ (2004). Oxidative metabolism of endocannabinoids by COX-2. Curr Pharm Des 10: 659667.
  • Kozak KR, Prusakiewicz JJ, Rowlinson SW, Prudhomme DR, Marnett LJ (2003). Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. Biochemistry 42: 90419049.
  • Kozak KR, Prusakiewicz JJ, Rowlinson SW, Schneider C, Marnett LJ (2001). Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. J Biol Chem 276: 3007230077.
  • Kozak KR, Rowlinson SW, Marnett LJ (2000). Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 275: 3374433749.
  • La Rana G, Russo R, Campolongo P, Bortolato M, Mangieri RA, Cuomo V et al. (2006). Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther 317: 13651371.
  • Lang W, Qin C, Lin S, Khanolkar AD, Goutopoulos A, Fan P et al. (1999). Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem 42: 896902.
  • Lau AH, Chow SS (2003). Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. Eur J Pharmacol 464: 229235.
  • Lever IJ, Masuda K, Cravatt BF, Rice ASC (2006). Immunohistochemical localisation of anandamide degrading enzyme: fatty acid amide hydrolase (FAAH) in rat dorsal root ganglion and spinal cord tissue. 16th Annual Symposium of International Cannabinoid Research Society, http://cannabinoidsociety.org/symposium.2006/2006.ICRS.Program.and.Abstracts.pdf.
  • Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL et al. (2004). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311: 441448.
  • Ligresti A, Morera E, Van Der Stelt M, Monory K, Lutz B, Ortar G et al. (2004). Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J 380: 265272.
  • Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Fowler CJ, Tiger G, de Lago E et al. (2003). Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J Med Chem 46: 15121522.
  • Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Lastres-Becker I, Gonzalez S, Fernandez-Ruiz J et al. (2001). Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J Med Chem 44: 45054508.
  • Maccarrone M, Fiorucci L, Erba F, Bari M, Finazzi-Agro A, Ascoli F (2000a). Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett 468: 176180.
  • Maccarrone M, Salvati S, Bari M, Finazzi A (2000b). Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. Biochem Biophys Res Commun 278: 576583.
  • Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M et al. (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor Type 1 and transient receptor potential vanilloid Type-1 receptors. J Pharmacol Exp Ther 316: 969982.
  • Maione S, de Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E et al. (2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150: 766781.
  • Malan Jr TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T et al. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239245.
  • Matsunaga A, Kawamoto M, Shiraishi S, Yasuda T, Kajiyama S, Kurita S et al. (2007). Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats. Eur J Pharmacol 554: 1217.
  • McFarland MJ, Barker EL (2004). Anandamide transport. Pharmacol Ther 104: 117135.
  • Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 8390.
  • Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H et al. (2006). Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126: 102114.
  • Moody JS, Kozak KR, Ji C, Marnett LJ (2001). Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. Biochemistry 40: 861866.
  • Muccioli GG, Xu C, Odah E, Cudaback E, Cisneros JA, Lambert DM et al. (2007). Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J Neurosci 27: 28832889.
  • Nackley AG, Makriyannis A, Hohmann AG (2003a). Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119: 747757.
  • Nackley AG, Suplita II RL, Hohmann AG (2003b). A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 117: 659670.
  • Oka S, Yanagimoto S, Ikeda S, Gokoh M, Kishimoto S, Waku K et al. (2005). Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. J Biol Chem 280: 1848818497.
  • Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V (2003). Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65: 14731481.
  • Ortega-Gutierrez S, Hawkins EG, Viso A, Lopez-Rodriguez ML, Cravatt BF (2004). Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry 43: 818481890.
  • Pacher P, Batkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389462.
  • Palazzo E, de Novellis V, Petrosino S, Marabese I, Vita D, Giordano C et al. (2006). Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur J Neurosci 24: 20112020.
  • Paylor B, Holt S, Fowler CJ (2006). The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacol Res 54: 481485.
  • Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63: 569611.
  • Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S et al. (2007). Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52: 415422.
  • Phillis JW, Horrocks LA, Farooqui AA (2006). Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 52: 201243.
  • Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A et al. (2003). Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99: 955960.
  • Rawls SM, Ding Z, Cowan A (2006). Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats. Pharmacol Biochem Behav 83: 508516.
  • Richardson D, Jhaveri MD, Kendall DA, Barrett DA, Chapman V (2007). Effects of inhibition of FAAH on levels of endocannabinoids in the hindpaw and spinal cord of rats with a carrageenan-induced inflamed hindpaw. British Pharmacological Society and 3rd European Workshop on Cannabinoid Research PO33.
  • Robinson I, Richardson D, Jhaveri MD, Barrett DA, Kendall DA, Chapman V (2006). Effects of fatty acid amide hydrolase and cyclooxygenase-2 inhibitors on nociceptive behaviour in the carrageenan model of inflammatory pain in rats. Proceedings of British Pharmacological Society Meeting Dec 2006, http://www.pa2online.org/abstracts/Vol4Issue2abst093P.pdf.
  • Robinson I, Richardson D, Jhaveri MD, Barrett DA, Kendall DA, Chapman V (2007). Effects of inhibition of cyclooxygenase 2 on levels of endocannabinoids in the carrageenan model of inflammatory pain. British Pharmacological Society and 3rd European Workshop on Cannabinoid Research PO34.
  • Rodella LF, Borsani E, Rezzani R, Ricci F, Buffoli B, Bianchi R (2005). AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. Eur J Pharmacol 508: 139146.
  • Russo R, Loverme J, La Rana G, Compton T, Parrot J, Duranti A et al. (2007). The fatty-acid amide hydrolase inhibitor URB597 (cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322: 236242.
  • Sagar DR, Kelly S, Millns PJ, O'Shaughnessey CT, Kendall DA, Chapman V (2005). Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22: 371379.
  • Samson MT, Small-Howard A, Shimoda LM, Koblan-Huberson M, Stokes AJ, Turner H (2003). Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170: 49534962.
  • Sang N, Zhang J, Chen C (2006). PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. J Physiol 572: 735745.
  • Scott DA, Wright CE, Angus JA (2004). Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109: 124131.
  • Stander S, Schmelz M, Metze D, Luger T, Rukwied R (2005). Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38: 177188.
  • Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 8997.
  • Svensson CI, Yaksh TL (2002). The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 42: 553583.
  • Takahashi M, Kawaguchi M, Shimada K, Nakashima T, Furuya H (2005). Systemic meloxicam reduces tactile allodynia development after L5 single spinal nerve injury in rats. Reg Anesth Pain Med 30: 351355.
  • Thomas H (1996). A community survey of adverse effects of cannabis use. Drug Alcohol Depend 42: 201207.
  • Ueda N (2002). Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat 68–69: 521534.
  • Ueda N, Goparaju SK, Katayama K, Kurahashi Y, Suzuki H, Yamamoto S (1998). A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors. J Med Invest 45: 2736.
  • Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48: 658672.
  • Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ (2007). Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 150: 186191.
  • Walker JM, Huang SM (2002). Cannabinoid analgesia. Pharmacol Ther 95: 127135.
  • Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999). Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96: 1219812203.
  • Weber A, Ni J, Ling KH, Acheampong A, Tang-Liu DD, Burk R et al. (2004). Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J Lipid Res 45: 757763.
  • Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS et al. (2005). A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol 528: 6572.
  • Woodward DF, Phelps RL, Krauss AH, Weber A, Short B, Chen J et al. (2004). Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev 22: 103120.
  • Yaksh TL, Dirig DM, Conway CM, Svensson C, Luo ZD, Isakson PC (2001). The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 21: 58475853.
  • Yu M, Ives D, Ramesha CS (1997). Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272: 2118121186.
  • Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC (1997). Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 283: 10691075.